Epsilon Healthcare has entered into an exclusive partnership with Canadian firm The Valens Company, giving Valens the ability to deliver Good Manufacturing Practice (GMP) grade products in Australia, New Zealand, Latin America, Europe, and Asia-Pacific.

The partnership will give Valens access to Epsilon’s GMP facility in Southport, Queensland and will see the first GMP-manufactured products sold through Valens in Australia.

THC Global CFO Jarrod White
Epsilon CEO Jarrod White

The first products manufactured under the partnership are expected to be delivered in the coming weeks and will be distributed through Valens’ Australian distribution partner Cannvalate. It will be the largest quantity of products provided to Cannvalate for distribution to date. 

Valens will fund all operational and capital expenditure on the Southport facility in return for preferential access and up to 85% of the operational capacity of the facility for the next five years, with an option to extend for six more. Valens will also provide operational and management consultancy. 

Epsilon CEO Jarrod White said: “Epsilon’s partnership with Valens as a leading manufacturer of cannabis products is complementary to our facility, being the largest TGA and EU GMP facility in the southern hemisphere. 

Cannvalate CEO Dr Sud Agarwal

“We are excited to be working with Valens during such a flourishing time in their corporate trajectory. Valens also shows a promising production throughput to scale up our GMP manufacturing capability.”

Cannvalate CEO Dr Sud Agarwal added: “We are excited to be working with Epsilon on further developing Australia’s largest GMP cannabinoid manufacturing facility. With New Zealand already moving to a pure GMP cannabinoid marketplace and Australia scheduled to follow suit soon, we see GMP-licensed facilities like Epsilon as having significant competitive advantages.”

Epsilon will also acquire AlternaMed from Cannvalate, including its portfolio of pending patent applications for three novel cannabinoid therapeutic agents targeting irritable bowel syndrome, menstrual pain, and smoking cessation and access to a Sigma Pharmaceuticals storage facility for Schedule 8 medicines.